Johnson & Johnson Announces Additional Data On IMAAVY Throughout 12 Abstracts At European Academy Of Neurology 2026 Congress; Participants Demonstrated Greater Reductions In MG-ADLe Scores; IMAAVY plus SOC Lowered Symptom Severity, Enhanced Daily Functioning At Week 24

Loading news article.

Johnson & Johnson Announces Additional Data On IMAAVY Throughout 12 Abstracts At European Academy Of Neurology 2026 Congress; Participants Demonstrated Greater Reductions In MG-ADLe Scores; IMAAVY plus SOC Lowered Symptom Severity, Enhanced Daily Functioning At Week 24 | WAPE

Johnson & Johnson Announces Additional Data On IMAAVY Throughout 12 Abstracts At European Academy Of Neurology 2026 Congress; Participants Demonstrated Greater Reductions In MG-ADLe Scores; IMAAVY plus SOC Lowered Symptom Severity, Enhanced Daily Functioning At Week 24

Article summary

Related companies

Comments —